Pfizer INC Form 4 insider transactions

Pfizer Inc. Director Joseph Echevarria acquired 1,908.003 phantom stock units as deferred compensation, increasing his beneficial ownership to 140,751.406 units.

Pfizer's Chairman and CEO, Albert Bourla, acquired 25 phantom stock units on June 30, 2025, increasing his total beneficial ownership to 718,220 units.

Pfizer Inc. Chairman and CEO Albert Bourla has acquired 24 additional phantom stock units, valued at $24.54 each, as part of a deferred compensation plan.

Pfizer's Chairman and CEO, Albert Bourla, has reported the acquisition of 26 phantom stock units as part of the company's Nonfunded Deferred Compensation and Supplemental Savings Plan.

Pfizer's CEO, Albert Bourla, reports acquiring 27 phantom stock units under the company's deferred compensation plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 25 phantom stock units on April 30, 2025, according to a Form 4 filing with the SEC.

Director Suzanne Nora Johnson acquired 8,999 phantom stock units of Pfizer Inc. as part of deferred compensation.

Director Ronald E. Blaylock reports acquisition of 8,999 phantom stock units of Pfizer Inc. on April 24, 2025, as part of deferred compensation.

Director Mortimer J. Buckley acquired 8,999 phantom stock units of Pfizer Inc. as part of a deferred compensation plan.

Director Susan Desmond-Hellmann acquired 8,999 phantom stock units of Pfizer as part of a deferred compensation plan.

Director Joseph Echevarria acquired 8,999 phantom stock units of Pfizer Inc. as part of a deferred compensation plan.

Director Scott Gottlieb acquired 8,999 phantom stock units in Pfizer, Inc. as part of a deferred compensation plan.

Director Susan Hockfield acquired 8,999 phantom stock units of Pfizer Inc. as part of deferred compensation.

Director Dan R. Littman reports acquisition of phantom stock units in Pfizer Inc. through a nonfunded deferred compensation plan.

Director Shantanu Narayen acquired 8,999 phantom stock units of Pfizer as part of a deferred compensation plan.

Director James Quincey acquired 8,999 phantom stock units of Pfizer as part of a deferred compensation plan.

Director James C. Smith reports acquisition of phantom stock units in Pfizer Inc. through a nonfunded deferred compensation plan.

Director Cyrus Taraporevala reports acquisition of 8,999 phantom stock units of Pfizer Inc. on April 24, 2025, as part of deferred compensation.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 45 phantom stock units in a recent SEC filing.

Pfizer's Chairman and CEO, Albert Bourla, reports the acquisition of 1,484 phantom stock units through the company's deferred compensation plan.

Director Cyrus Taraporevala reported the acquisition of phantom stock units representing deferred director's compensation.

Director James C. Smith reports acquisition of phantom stock units representing deferred compensation from Pfizer.

Director James Quincey reports acquisition of phantom stock units representing deferred director's compensation.

Director Shantanu Narayen reports acquisition of phantom stock units representing deferred director's compensation.

Director Joseph Echevarria reports acquisition of phantom stock units representing deferred compensation from Pfizer.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of phantom stock units under the company's deferred compensation plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 1,905 phantom stock units through the company's deferred compensation plan.

Executive Vice President Andrew Baum reports the acquisition of stock appreciation rights (SARs) convertible to Pfizer common stock.

Pfizer's Chief Financial Officer, David Denton, acquired stock appreciation rights (SARs) that will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Executive Vice President Aamir Malik acquired stock appreciation rights (SARs) convertible to 371,824 shares of Pfizer common stock, according to a Form 4 filing with the SEC.